📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis. (2022)

First Author: Barry LE

Attributed to: Integrative genomic, epigenetic and functional studies in diabetic kidney disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0274136

PubMed Identifier: 36331936

Publication URI: http://europepmc.org/abstract/MED/36331936

Type: Journal Article/Review

Volume: 17

Parent Publication: PloS one

Issue: 11

ISSN: 1932-6203